NAFLD is a leading comorbidity in HIV with an exaggerated course compared to the general population.
Tesamorelin has been demonstrated to reduce liver fat and prevent
fibrosis progression in HIV-associated
NAFLD. We further showed that
tesamorelin downregulated hepatic gene sets involved in
inflammation, tissue repair, and cell division. Nonetheless, effects of
tesamorelin on individual
plasma proteins pertaining to these pathways are not known. Leveraging our prior randomized-controlled trial and transcriptomic approach, we performed a focused assessment of 9
plasma proteins corresponding to top leading edge genes within differentially modulated gene sets.
Tesamorelin led to significant reductions in
vascular endothelial growth factor A (VEGFA, log2-fold change - 0.20 ± 0.35 vs. 0.05 ± 0.34, P = 0.02),
transforming growth factor beta 1 (TGFB1, - 0.35 ± 0.56 vs. - 0.05 ± 0.43, P = 0.05), and
macrophage colony stimulating factor 1 (CSF1, - 0.17 ± 0.21 vs. 0.02 ± 0.20, P = 0.004) versus placebo. Among
tesamorelin-treated participants, reductions in plasma VEGFA (r = 0.62, P = 0.006) and CSF1 (r = 0.50, P = 0.04) correlated with a decline in
NAFLD activity score. Decreases in TGFB1 (r = 0.61, P = 0.009) and CSF1 (r = 0.64, P = 0.006) were associated with reduced gene-level
fibrosis score.
Tesamorelin suppressed key angiogenic, fibrogenic, and pro-inflammatory mediators. CSF1, a regulator of monocyte recruitment and activation, may serve as an innovative therapeutic target for
NAFLD in HIV. Clinical Trials Registry Number: NCT02196831.